BG103946A - Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак - Google Patents

Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак Download PDF

Info

Publication number
BG103946A
BG103946A BG103946A BG10394699A BG103946A BG 103946 A BG103946 A BG 103946A BG 103946 A BG103946 A BG 103946A BG 10394699 A BG10394699 A BG 10394699A BG 103946 A BG103946 A BG 103946A
Authority
BG
Bulgaria
Prior art keywords
alkyl
phenyl
coa reductase
inhibitor
hmg coa
Prior art date
Application number
BG103946A
Other languages
Bulgarian (bg)
English (en)
Inventor
Shama Kajiji
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103946A publication Critical patent/BG103946A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG103946A 1997-06-16 1999-12-03 Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак BG103946A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
BG103946A true BG103946A (bg) 2000-07-31

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103946A BG103946A (bg) 1997-06-16 1999-12-03 Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак

Country Status (37)

Country Link
EP (1) EP0986387B1 (pt)
JP (1) JP3713051B2 (pt)
KR (1) KR100392573B1 (pt)
CN (1) CN1259868A (pt)
AP (1) AP9801261A0 (pt)
AR (1) AR013090A1 (pt)
AT (1) ATE235905T1 (pt)
BG (1) BG103946A (pt)
BR (1) BR9810616A (pt)
CA (1) CA2294399C (pt)
CO (1) CO4950607A1 (pt)
DE (1) DE69812933T2 (pt)
DK (1) DK0986387T3 (pt)
DZ (1) DZ2518A1 (pt)
EA (1) EA199901043A1 (pt)
ES (1) ES2196559T3 (pt)
GT (1) GT199800081A (pt)
HN (1) HN1998000091A (pt)
HR (1) HRP980328B1 (pt)
HU (1) HUP0004624A3 (pt)
ID (1) ID23014A (pt)
IL (1) IL132765A0 (pt)
IS (1) IS5259A (pt)
MA (1) MA24569A1 (pt)
NO (1) NO996206L (pt)
NZ (1) NZ500662A (pt)
OA (1) OA11231A (pt)
PA (1) PA8453601A1 (pt)
PE (1) PE82899A1 (pt)
PL (1) PL337651A1 (pt)
PT (1) PT986387E (pt)
SK (1) SK169699A3 (pt)
TN (1) TNSN98088A1 (pt)
TR (1) TR199903074T2 (pt)
UA (1) UA57081C2 (pt)
WO (1) WO1998057633A1 (pt)
ZA (1) ZA985182B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003860B1 (ru) * 1998-05-12 2003-10-30 Варнер-Ламберт Компани КОМБИНАЦИИ ИНГИБИТОРОВ ПРОТЕИН ФАРНЕЗИЛТРАНСФЕРАЗЫ И HMG KoA РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

Also Published As

Publication number Publication date
JP3713051B2 (ja) 2005-11-02
HUP0004624A2 (hu) 2001-10-28
JP2000513031A (ja) 2000-10-03
NO996206L (no) 2000-02-15
CO4950607A1 (es) 2000-09-01
GT199800081A (es) 1999-12-07
SK169699A3 (en) 2000-06-12
AU724676B2 (en) 2000-09-28
PL337651A1 (en) 2000-08-28
ZA985182B (en) 1999-12-17
HN1998000091A (es) 1999-09-29
AR013090A1 (es) 2000-12-13
OA11231A (en) 2003-05-26
IS5259A (is) 1999-11-19
MA24569A1 (fr) 1998-12-31
NO996206D0 (no) 1999-12-15
CN1259868A (zh) 2000-07-12
HRP980328B1 (en) 2002-06-30
ID23014A (id) 1999-12-30
DE69812933T2 (de) 2003-11-06
PA8453601A1 (es) 2000-05-24
BR9810616A (pt) 2000-09-12
ATE235905T1 (de) 2003-04-15
TNSN98088A1 (fr) 2005-03-15
KR100392573B1 (ko) 2003-07-23
ES2196559T3 (es) 2003-12-16
EP0986387A1 (en) 2000-03-22
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
WO1998057633A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
TR199903074T2 (xx) 2000-05-22
AP9801261A0 (en) 1999-12-11
DK0986387T3 (da) 2003-07-14
PT986387E (pt) 2003-06-30
KR20010013839A (ko) 2001-02-26
NZ500662A (en) 2001-10-26
AU7445998A (en) 1999-01-04
EA199901043A1 (ru) 2000-06-26
EP0986387B1 (en) 2003-04-02
HRP980328A2 (en) 1999-04-30
CA2294399A1 (en) 1998-12-23
DZ2518A1 (fr) 2003-02-01
PE82899A1 (es) 1999-08-26
IL132765A0 (en) 2001-03-19
DE69812933D1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
RU2448703C2 (ru) Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
JP6473330B2 (ja) ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法
JP4130179B2 (ja) 骨髄腫を処置するためのｃ−ｋｉｔ阻害剤の使用
KR101354237B1 (ko) 골수종 치료를 위한 ｈｄａｃ 저해제의 용도
BG103946A (bg) Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак
KR20010032304A (ko) 알도스 환원효소 억제제 및 글리코겐 포스포릴라제억제제의 혼합물
JPWO2002036117A1 (ja) 抗癌剤としての併用医薬組成物
ES2896735T3 (es) Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida
IL305317A (en) Preparations and methods for regulating hair growth
JP2000510828A (ja) 腫瘍崩壊剤および放射線療法の臨床効果を増強するためのプロテインキナーゼｃ阻害剤の使用
JP6864379B2 (ja) インドール類似体及びその使用
KR20010078803A (ko) 제약 복합제제
EA001779B1 (ru) Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
US20040077661A1 (en) Treatment of tuberous sclerosis associated neoplasms
AU2002211862B2 (en) Methods of inducing cancer cell death and tumor regression
AU724676C (en) Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US20030114503A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
CZ448699A3 (cs) Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
KR20000035861A (ko) Ａｉｄｓ 치료용 약제를 제조하기 위한 ｐｋｃ 억제제의 사용 방법
MXPA99011798A (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
EP3503888A1 (en) Inhibitors of-bcr-abl mutants and use thereof
JP4227121B2 (ja) 神経因性疼痛治療剤
WO2021086912A1 (en) Combined pikfyve and p38 map kinase inhibition for treating cancer
WO2024124000A1 (en) Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain